Literature DB >> 20586520

Financial and clinical characteristics of fibromyalgia: a case-control comparison.

Ana Palacio1, Claudia L Uribe, Hua Li, John Hanna, Michael Deminski, Jose Alvir, Arthi Chandran, Robert Sanchez.   

Abstract

OBJECTIVE: To compare healthcare utilization and costs between subjects with and without fibromyalgia (FM) using claims data from a large health benefits company in the United States. STUDY
DESIGN: Retrospective cohort.
METHODS: We analyzed 24 months of medical and pharmacy claims data comparing healthcare utilization and costs among Humana members diagnosed with FM to a propensity score matched control group without a diagnosis for FM. FM cases were identified as members aged 18 years and older, with at least 2 medical claims for International Classification of Diseases, Ninth Revision, Clinical Modification codes 729.0 and/or 729.1. The first medical claim for FM was utilized as the index date.
RESULTS: A total of 9988 FM cases and 9988 controls were included in the analysis. Compared with controls, the use of pain-related medications by FM cases was approximately 2 times higher with opioids being used most commonly. FM cases utilized a mean (SD) of 22.5 (23.9) and 31.1 (26.6) outpatient services per year in the prediagnosis and postdiagnosis periods, respectively, compared with 14.8 (20.5) and 16.3 (24.5) among controls (P <.01). Office visits, tests, and procedures represented the majority of utilization. During the postdiagnosis period, the mean per-patient per-month costs for outpatient services among FM cases was $377 ($760) and $217 ($740.87) among controls (P <.01).
CONCLUSION: FM cases had significantly higher utilization and costs compared with controls. Office visits, tests and procedures, and the use of pain-related medications accounted for the largest absolute differences between the 2 groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586520

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  Healthcare Costs Associated With Chronic Opioid Use and Fibromayalgia Syndrome.

Authors:  Jacob T Painter; Leslie J Crofford; J S Butler; Jeffery Talbert
Journal:  Am J Pharm Benefits       Date:  2015-02-13

2.  Survey of physician experiences and perceptions about the diagnosis and treatment of fibromyalgia.

Authors:  Serge Perrot; Ernest Choy; Danielle Petersel; Anna Ginovker; Erich Kramer
Journal:  BMC Health Serv Res       Date:  2012-10-10       Impact factor: 2.655

3.  Electronic medical record data to identify variables associated with a fibromyalgia diagnosis: importance of health care resource utilization.

Authors:  Elizabeth T Masters; Jack Mardekian; Birol Emir; Andrew Clair; Max Kuhn; Stuart L Silverman
Journal:  J Pain Res       Date:  2015-03-05       Impact factor: 3.133

4.  Fibromyalgia-related costs and loss of productivity: a substantial societal burden.

Authors:  Anaïs Lacasse; Patricia Bourgault; Manon Choinière
Journal:  BMC Musculoskelet Disord       Date:  2016-04-16       Impact factor: 2.362

5.  Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Authors:  X Peng; P Sun; D Novick; J Andrews; S Sun
Journal:  J Pain Res       Date:  2014-01-09       Impact factor: 3.133

6.  The relationship between serum leptin level and disease activity and inflammatory markers in fibromyalgia patients.

Authors:  Safinaz Ataoglu; Handan Ankarali; Rumeysa Samanci; Mustafa Ozsahin; Ozlem Admis
Journal:  North Clin Istanb       Date:  2018-04-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.